SFM
VTGN icon

Sphera Funds Management’s VistaGen Therapeutics VTGN Stock Holding History

Sphera Funds Management’s Portfolio VTGN Stock Details VTGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-447,939
Closed -$896K – 139
2025
Q2 		$896K Sell
447,939
-342,611
-43% -$778K 0.21% 91
2025
Q1 		$1.98M Sell
790,550
-18,000
-2% -$50.9K 0.46% 68
2024
Q4 		$2.39M Hold
808,550
– – 0.43% 74
2024
Q3 		$2.43M Hold
808,550
– – 0.39% 73
2024
Q2 		$2.81M Hold
808,550
– – 0.38% 71
2024
Q1 		$4.27M Hold
808,550
– – 0.6% 54
2023
Q4 		$4.16M Buy
808,550
+708,550
+709% +$2.68M 0.67% 56
2023
Q3 		$524K Buy
+100,000
New +$444K 0.1% 80
2022
Q3 		– Sell
-109,705
Closed -$2.9M – 88
2022
Q2 		$2.9M Sell
109,705
-55,342
-34% -$1.95M 0.31% 33
2022
Q1 		$6.14M Buy
165,047
+30,882
+23% +$1.35M 0.87% 33
2021
Q4 		$7.85M Buy
134,165
+6,667
+5% +$434K 0.86% 39
2021
Q3 		$10.5M Sell
127,498
-8,524
-6% -$741K 0.88% 34
2021
Q2 		$12.9M Sell
136,022
-3,217
-2% -$238K 0.87% 31
2021
Q1 		$8.9M Buy
139,239
+48,406
+53% +$3.23M 0.68% 35
2020
Q4 		$5.29M Buy
+90,833
New +$2.32M 0.47% 65
2019
Q3 		– Sell
-22,454
Closed -$489K – 102
2019
Q2 		$489K Sell
22,454
-44,948
-67% -$1.19M 0.07% 83
2019
Q1 		$2.59M Buy
67,402
+18,271
+37% +$797K 0.24% 83
2018
Q4 		$2.21M Sell
49,131
-6,666
-12% -$363K 0.25% 71
2018
Q3 		$2.43M Buy
55,797
+10,067
+22% +$408K 0.28% 81
2018
Q2 		$1.88M Buy
45,730
+4,155
+10% +$144K 0.26% 84
2018
Q1 		$1.16M Hold
41,575
– – 0.18% 81
2017
Q4 		$1.38M Buy
41,575
+6,295
+18% +$208K 0.16% 107
2017
Q3 		$1.69M Buy
35,280
+17,143
+95% +$903K 0.24% 91
2017
Q2 		$1.02M Hold
18,137
– – 0.17% 105
2017
Q1 		$1.07M Hold
18,137
– – 0.21% 92
2016
Q4 		$2.03M Hold
18,137
– – 0.51% 56
2016
Q3 		$2.26M Buy
18,137
+8,334
+85% +$905K 0.37% 68
2016
Q2 		$1.15M Buy
+9,803
New +$1.12M 0.3% 75

Other funds holding VTGN

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Sphera Funds Management's VTGN Position: Q3 2025 in Review

Sphera Funds Management sold out of VistaGen Therapeutics (VTGN) in Q3 2025, closing a stake of 447,939 shares — an estimated $896K sold.

Sphera Funds Management first reported a position in VTGN in Q2 2016 and held it in 28 quarters. The position peaked at $12.9M in Q2 2021. 58 funds tracked by Wall St. Rank hold VTGN as of Q3 2025.

  • Sphera Funds Management reported no remaining VistaGen Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Sphera Funds Management sold 447,939 VistaGen Therapeutics shares in Q3 2025, an estimated $896K.
  • Sphera Funds Management first reported a position in VistaGen Therapeutics in Q2 2016 and held it in 28 quarters.
  • Sphera Funds Management's VistaGen Therapeutics position peaked at $12.9M in Q2 2021.
  • 58 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q3 2025.

Based on Sphera Funds Management's 13F filing for Q3 2025, filed 14 Nov 2025.